NEW YORK (GenomeWeb) – Myriad Genetics has signed a three-year contract with national payor UnitedHealthcare to provide access to its next-generation sequencing myRisk Hereditary Cancer test to beneficiaries who meet certain eligibility criteria for hereditary cancer risk.

The myRisk test gauges 25 genes associated with eight hereditary cancers, including breast, colon, ovarian, endometrial, pancreatic, prostate, and gastric cancers, and melanoma.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PLOS this week: genomic analysis of Malaysian tuberculosis strain, database of bat genomes, and more.

An editorial appearing at The Scientist bemoans the high numbers of mitochondrial genome papers and suggests a different path for mitochondrial genome research.

Researchers and drug developers are excited about the potential of CRISPR-Cas9-based therapeutics, the Wall Street Journal reports.

US lawmakers want to develop a new incarnation of the National Children's Study, ScienceInsider reports.